Integrated Filing — IndAS

General information about company
Scrip Code	500124
NSE Symbol	DRREDDY
MSEI Symbol	NOTLISTED
ISIN	INE089A01031
Name of company	Dr. Reddy's Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	09-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	21-Mar-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Multi segment
Description of single segment
Start date and time of board meeting	09-May-2025   09:00:00
End date and time of board meeting	09-May-2025   15:45:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	85284000000	326439000000
	Other income	5221000000	10973000000
	Total income	90505000000	337412000000
2	Expenses
(a)	Cost of materials consumed	17165000000	56835000000
(b)	Purchases of stock-in-trade	11275000000	48411000000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	60000000	-5447000000
(d)	Employee benefit expense	14006000000	55800000000
(e)	Finance costs	656000000	2829000000
(f)	Depreciation, depletion and amortisation expense	4547000000	17037000000
(f)	Other Expenses
1	Impairment of non- current assets,net	768000000	1693000000
2	Other expenses	22031000000	83676000000
	Total other expenses	22799000000	85369000000
	Total expenses	70508000000	260834000000
3	Total profit before exceptional items and tax	19997000000	76578000000
4	Exceptional items	0	0
5	Total profit before tax	19997000000	76578000000
6	Tax expense
7	Current tax	4323000000	22581000000
8	Deferred tax	-138000000	-3038000000
9	Total tax expenses	4185000000	19543000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	15812000000	57035000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	55000000	217000000
16	Total profit (loss) for period	15867000000	57252000000
17	Other comprehensive income net of taxes	1094000000	2049000000
18	Total Comprehensive Income for the period	16961000000	59301000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	15933000000	56551000000
	Total profit or loss, attributable to non-controlling interests	-66000000	-66000000
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	17027000000	58600000000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-66000000	701000000
21	Details of equity share capital
	Paid-up equity share capital	834000000	834000000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		334662000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	19.12	67.89
	Diluted earnings (loss) per share from continuing operations	19.1	67.79
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	19.12	67.89
	Diluted earnings (loss) per share from continuing and discontinued operations	19.1	67.79
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	72984000000
	Capital work-in-progress	23994000000
	Investment property	0
	Goodwill	13139000000
	Other intangible assets	96141000000
	Intangible assets under development	662000000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	4811000000
	Non-current financial assets
	Non-current investments	2393000000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	8875000000
	Total non-current financial assets	11268000000
	Deferred tax assets (net)	18325000000
	Other non-current assets	2761000000
	Total non-current assets	244085000000
2	Current assets
	Inventories	71085000000
	Current financial asset
	Current investments	33307000000
	Trade receivables, current	90420000000
	Cash and cash equivalents	14654000000
	Bank balance other than cash and cash equivalents	9948000000
	Loans, current	0
	Other current financial assets	3699000000
	Total current financial assets	152028000000
	Current tax assets (net)	0
	Other current assets	27068000000
	Total current assets	250181000000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	494266000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	834000000
	Other equity	334662000000
	Total equity attributable to owners of parent	335496000000
	Non controlling interest	3778000000
	Total equity	339274000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	3800000000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	4262000000
	Total non-current financial liabilities	8062000000
	Provisions, non-current	298000000
	Deferred tax liabilities (net)	14038000000
	Deferred government grants, Non-current	0
	Other non-current liabilities	2256000000
	Total non-current liabilities	24654000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	38045000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	210000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	26268000000
	Total Trade payable	26478000000
	Other current financial liabilities	41841000000
	Total current financial liabilities	106364000000
	Other current liabilities	13190000000
	Provisions, current	7756000000
	Current tax liabilities (Net)	3028000000
	Deferred government grants, Current	0
	Total current liabilities	130338000000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	154992000000
	Total equity and liabilites	494266000000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	a) Pharmaceutical Services and Active Ingredients	11819000000	43868000000
2	b) Global Generics	75432000000	289810000000
3	c) Others	145000000	2150000000
	Total Segment Revenue	87396000000	335828000000
	Less: Inter segment revenue	2112000000	2112000000
	Revenue from operations	85284000000	326439000000
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	a) Pharmaceutical Services and Active Ingredients	2526000000	9178000000
2	b) Global Generics	44707000000	179606000000
3	c) Others	40000000	1665000000
	Total Profit before tax	47273000000	190449000000
	i. Finance cost	0	0
	ii. Other Unallocable Expenditure net off Unallocable income	27221000000	27221000000
	Profit before tax	20052000000	76795000000
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	a) Pharmaceutical Services and Active Ingredients	0	0
2	b) Global Generics	0	0
3	c) Others	0	0
	Total Segment Asset	0	0
	Un-allocable Assets	0	0
	Net Segment Asset	0	0
4	Segment Liabilities
	Segment Liabilities
1	a) Pharmaceutical Services and Active Ingredients	0	0
2	b) Global Generics	0	0
3	c) Others	0	0
	Total Segment Liabilities	0	0
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	0	0
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	a) (i) Items that will not be reclassified subsequently to profit or loss	-117000000	-293000000
	Total Amount of items that will not be reclassified to profit and loss	-117000000	-293000000
2	Income tax relating to items that will not be reclassified to profit or loss	-24000000	-24000000
3	Amount of items that will be reclassified to profit and loss
1	b) (i) Items that will be reclassified subsequently to profit or loss	1425000000	2376000000
	Total Amount of items that will be reclassified to profit and loss	1425000000	2376000000
4	Income tax relating to items that will be reclassified to profit or loss	238000000	58000000
5	Total Other comprehensive income	1094000000	2049000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Consolidated
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			76578000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			2829000000
	Adjustments for decrease (increase) in inventories			-12753000000
	Adjustments for decrease (increase) in trade receivables, current			-10283000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-7293000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			340000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			0
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			17037000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			1693000000
	Adjustments for provisions, current			5220000000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			211000000
	Adjustments for dividend income			0
	Adjustments for interest income			2677000000
	Adjustments for share-based payments			424000000
	Adjustments for fair value losses (gains)			-3554000000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-1512000000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			161000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-10157000000
	Net cash flows from (used in) operations			66421000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			19993000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			46428000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			53096000000
	Other cash receipts from sales of equity or debt instruments of other entities			286632000000
	Other cash payments to acquire equity or debt instruments of other entities			254458000000
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			317000000
	Proceeds from sales of property, plant and equipment			512000000
	Purchase of property, plant and equipment			27504000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			6894000000
	Proceeds from sales of intangible assets under development			732000000
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			3372000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) investing activities	-51021000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			193000000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			1389000000
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			24490000000
	Repayments of borrowings			0
	Payments of lease liabilities			1294000000
	Dividends paid			6662000000
	Interest paid			3483000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			11855000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			7262000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			224000000
	Net increase (decrease) in cash and cash equivalents			7486000000
	Cash and cash equivalents cash flow statement at beginning of period			7107000000
	Cash and cash equivalents cash flow statement at end of period			14593000000